Proprietary & Confidential—This material is proprietary to My Life Spark P.C. Unauthorized use, reproduction, or distribution is strictly prohibited.

Survivorship · GLP-1 series

GLP-1 therapy in cancer survivorship, module by module.

Ten presentations covering cardio-oncology relevance, safety and titration, lean-mass preservation, weight regain after stopping, virtual care, coverage, and shared decision-making. Each module has its own page, slide deck, and video. Videos are being recorded now; the placeholders below will fill in as each one is published.

Video gallery

10 modules · educational use only, not medical advice.

Module 1 · Cardio-oncology

GLP-1–Based Therapies in Cardio-Oncology

Where GLP-1 biology meets survivorship: cardiometabolic risk reduction across the cancer journey, the muscle guardrail, and a prescribing-to-prevention pathway.

Module 2 · Full field guide

GLP-1 Receptor Agonist Therapy: The Complete Briefing

Eleven themes from initiation through emerging evidence — titration ladders, tolerability, switching, lean mass, cardiovascular benefit, regain, virtual care, coverage, and communication.

Module 3 · Evidence · cost · coverage

Obesity, Cardiometabolic Health & GLP-1 Therapies

How the agents work, SURMOUNT-5 head-to-head weight loss, SELECT cardiovascular benefit, safety, cost, coverage, and adherence.

Module 4 · Safety

Managing Adverse Effects & Safety Considerations

The gastrointestinal signal that dominates, the rare-but-serious risks, why stepwise escalation limits harm, and what to monitor.

Module 5 · Case-based

Avoiding Common GLP-1 Prescribing Mistakes

Six errors that drive denials and harm — indication mismatch, fast titration, missed contraindications, interactions, compounded use, and thin documentation.

Module 6 · Muscle

Preserving Lean Mass During GLP-1 Weight Loss

Not all weight lost should be muscle. Why lean mass matters for survivors, and the four levers that protect it during rapid weight loss.

Module 7 · The exit plan

Weight Regain After GLP-1 Discontinuation

Stopping therapy tends to reverse the gains. The regain trajectory, who is at highest risk, and how to plan the off-ramp before it happens.

Module 8 · Delivery

Virtual Care Models for Obesity & Cardiometabolic Disease

Convenience is real; so are the gaps. What good telehealth GLP-1 care looks like, and the guardrails that separate it from a prescription pipeline.

Module 9 · Communication

Patient Communication & Shared Decision-Making

The SHARE approach, the Ottawa framework, decision aids, teach-back, and how a documented shared decision supports medical necessity.

Module 10 · Myths

GLP-1 Receptor Agonists: Myths, Misconceptions & Media Headlines

What a GLP-1 actually is, four brands and two molecules, the myths worth retiring, and the difference between an exciting signal and an oversold headline.

Educational information only. It does not replace advice from your oncology or primary care team, and no treatment decision should be made from these modules alone.